About Spectra Biomedical
Discovering and developing novel pharmaceuticals to treat neuropsychiatric and other multifactorial diseases. The unmet therapeutic needs of neuropsychiatric disorders alone have been estimated to represent an annual market potential of more than five billion dollars. Spectra believes that it can generate important pharmaceutical products for this market by applying molecular genetic technologies to clinically evaluated human DNA databases. The company has identified families that are willing to cooperate on the analysis of various disorders over a prolonged period of time. These familial samples can also be used to determine the clinical relevance of newly discovered genes. Taking this approach, Spectra has identified novel targets for the discovery of new diagnostics and therapeutics for migraine, depression, and other diseases.